PCSK9通过非低密度脂蛋白胆固醇途径影响心血管疾病的研究进展  

Research progress of PCSK9 affecting cardiovascular diseases through non-low-density lipoprotein cholestero-l pathway

作　　者：任阳荷 王红[1] 李为民[1] REN Yanghe;WANG Hong;LI Weimin(Department of Cardiology,the First Hospital of Harbin Medical University,Harbin,150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院心内科,哈尔滨150001

出　　处：《临床心血管病杂志》2023年第7期563-567,共5页Journal of Clinical Cardiology

摘　　要：前蛋白转化酶枯草杆菌蛋白酶/kexin 9(PCSK9)是前蛋白转化酶家族的第9个成员,是一组丝氨酸蛋白酶,主要由肝脏分泌并释放到血液,通过降解低密度脂蛋白受体(low-density lipoprotein receptor, LDLR)来升高低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C),从而促进动脉粥样斑块的形成。PCSK9抑制剂的出现为血脂异常的治疗开辟了新途径。近年来越来越多的研究表明,PCSK9不仅调节肝脏的脂质代谢,同时还参与肝外器官的生理病理过程,影响多种心血管疾病。本文就PCSK9与心血管疾病的最新进展进行综述。PCSK9, the ninth member of the proprotein convertase family, is a group of serine proteases secreted primarily by the liver and released into the bloodstream. There, it degrades the low-density lipoprotein receptor(LDLR) thus increasing low-density lipoprotein cholesterol(LDL-C) and promoting the formation of atherosclerotic plaque. The emergence of PCSK9 inhibitors has opened up a new way for the treatment of dyslipidemia. In recent years, more and more studies have shown that PCSK9 not only regulates lipid metabolism in the liver, but also participates in the physiological and pathological processes of extrahepatic organs, affecting a variety of cardiovascular diseases. This article reviews the latest progress of PCSK9 and cardiovascular diseases.

关 键 词：前蛋白转化酶枯草杆菌蛋白酶/kexin 9 心血管疾病 低密度脂蛋白胆固醇 PCSK9抑制剂 非低密度脂蛋白胆固醇 

分 类 号：R54[医药卫生—心血管疾病]